DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 7.7

Change

-0.17 (-2.10)%

Market Cap

USD 0.17B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.38 (+0.38%)

USD 18.39B
IVV:AU iShares Core S&P 500 AUD

-0.22 (-0.38%)

USD 11.33B
VGS:AU Vanguard MSCI International Sh..

-0.50 (-0.38%)

USD 10.39B
QUAL:AU VanEck Vectors MSCI World ex A..

-0.40 (-0.72%)

USD 7.35B
IOZ:AU Ishares Core S&P/Asx 200

+0.12 (+0.37%)

USD 6.40B
VTS:AU Vanguard US Total Market Share..

-1.88 (-0.44%)

USD 5.71B
STW:AU SPDR® S&P/ASX 200 Fund

+0.29 (+0.39%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

-0.10 (-0.22%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.14 (+0.35%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.43 (+0.32%)

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.04% 38% F 53% F
Dividend Return 0.35% 10% F 6% D-
Total Return -1.69% 36% F 51% F
Trailing 12 Months  
Capital Gain -8.66% 10% F 46% F
Dividend Return 2.97% 41% F 33% F
Total Return -5.69% 9% A- 46% F
Trailing 5 Years  
Capital Gain 17.02% 35% F 57% F
Dividend Return 11.12% 24% F 21% F
Total Return 28.14% 28% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 5.68% 61% D- 56% F
Dividend Return 7.58% 61% D- 55% F
Total Return 1.89% 54% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 8.30% 64% D 91% A-
Risk Adjusted Return 91.29% 84% B 94% A
Market Capitalization 0.17B 33% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.